<DOC>
	<DOCNO>NCT01390792</DOCNO>
	<brief_summary>The purpose post-marketing surveillance study collect information efficacy safety prophylactic administration zanamivir clinical practice family person live patient influenza virus infection .</brief_summary>
	<brief_title>Special Drug Use Investigation RelenzaÂ® ( Zanamivir ) ( Prophylaxis )</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Zanamivir</mesh_term>
	<criteria>Subjects meet study population criterion Subjects history hypersensitivity ingredient zanamivir</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>